Viral induction and targeted inhibition of galectin-1 in EBV + posttransplant lymphoproliferative disorders | ||
| dc.conicet.organizacion | Dana-Farber Cancer Institute. Department of Medical Oncology | |
| dc.conicet.organizacion | Dana-Farber Cancer Institute. Department of Medical Oncology | |
| dc.conicet.organizacion | Brigham and Women’s Hospital. Department of Pathology | |
| dc.conicet.organizacion | Dana-Farber Cancer Institute. Department of Medical Oncology | |
| dc.conicet.organizacion | Dana-Farber Cancer Institute. Department of Medical Oncology | |
| dc.conicet.organizacion | Brigham and Women’s Hospital. Department of Pathology | |
| dc.conicet.organizacion | Immune Disease Institute/Harvard Medical School. Center for Human Cell Therapy | |
| dc.conicet.organizacion | Dana-Farber Cancer Institute. Department of Medical Oncology | |
| dc.conicet.organizacion | Broad Institute | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i) | |
| dc.conicet.organizacion | Dana-Farber Cancer Institute. Department of Medical Oncology | |
| dc.conicet.organizacion | Brigham and Women’s Hospital. Department of Pathology | |
| dc.conicet.organizacion | Dana-Farber Cancer Institute. Department of Medical Oncology | |
| dc.contributor.author | Ouyang, Ying | |
| dc.contributor.author | Juszczynski, Przemyslaw | |
| dc.contributor.author | Rodig, Scott J. | |
| dc.contributor.author | Green, Michael R. | |
| dc.contributor.author | O´ Donnell, Evan | |
| dc.contributor.author | Currie, Treeve | |
| dc.contributor.author | Armant, Myriam | |
| dc.contributor.author | Takeyama, Kunihiko | |
| dc.contributor.author | Monti, Stefano | |
| dc.contributor.author | Rabinovich, Gabriel Adrián | |
| dc.contributor.author | Ritz, Jerome | |
| dc.contributor.author | Kutok, Jeffery L. | |
| dc.contributor.author | Shipp, Margaret A. | |
| dc.date.issued | 2011-06 | |
| dc.description.abstract | Posttransplant lymphoproliferative disorders (PTLDs) are potentially fatal, EBVdriven B-cell malignancies that develop in immunocompromised solid organ or hematopoietic stem cell recipients. In PTLD, the expression of EBV proteins, including latent membrane protein 1 (LMP1) and LMP2A, viral immune evasion strategies, and impaired host immune surveillance foster the proliferation of EBV-transformed B cells. Current PTLD treatment strategies include reduction of immunosuppression, which increases the risk of graft rejection, anti-CD20 treatment, combination chemotherapy, and administration of EBV-specific cytotoxic T cells. In the present study, we report that EBV-transformed lymphoblastoid Bcell lines (LCLs) and primary PTLDs overexpress galectin-1 (Gal1), a carbohydratebinding lectin that induces tolerogenic dendritic cells and triggers the selective apoptosis of CD4 Th1 and Th17 cells and cytotoxic T cells. In transcriptional reporter assays, LMP2A and LMP1 each increased Gal1-driven luciferase expression, and the combination of LMP2A and LMP1 was additive. In addition, small interfering RNA (siRNA)–mediated depletion of LMP2A decreased Gal1 protein abundance in EBV-transformed LCLs. Gal1 expression in LCLs was dependent on both activating protein 1 (AP-1) and PI3K. A newly developed neutralizing Gal1 mAb selectively inhibited Gal1-mediated apoptosis of EBV-specific CD8 T cells. Given the tolerogenic and immunosuppressive function of Gal1, antibody-mediated Gal1 neutralization may represent a novel immunotherapeutic strategy for PTLD and other Gal1-expressing tumors. | es |
| dc.description.fil | Fil: Ouyang, Ying. Dana-Farber Cancer Institute. Department of Medical Oncology; Estados Unidos | |
| dc.description.fil | Fil: Juszczynski, Przemyslaw. Dana-Farber Cancer Institute. Department of Medical Oncology; Estados Unidos | |
| dc.description.fil | Fil: Rodig, Scott J.. Brigham and Women’s Hospital. Department of Pathology; Estados Unidos | |
| dc.description.fil | Fil: Green, Michael R.. Dana-Farber Cancer Institute. Department of Medical Oncology; Estados Unidos | |
| dc.description.fil | Fil: O´ Donnell, Evan. Dana-Farber Cancer Institute. Department of Medical Oncology; Estados Unidos | |
| dc.description.fil | Fil: Currie, Treeve. Brigham and Women’s Hospital. Department of Pathology; Estados Unidos | |
| dc.description.fil | Fil: Armant, Myriam. Immune Disease Institute/Harvard Medical School. Center for Human Cell Therapy; Estados Unidos | |
| dc.description.fil | Fil: Takeyama, Kunihiko. Dana-Farber Cancer Institute. Department of Medical Oncology; Estados Unidos | |
| dc.description.fil | Fil: Monti, Stefano. Broad Institute; Estados Unidos | |
| dc.description.fil | Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina | |
| dc.description.fil | Fil: Ritz, Jerome. Dana-Farber Cancer Institute. Department of Medical Oncology; Estados Unidos | |
| dc.description.fil | Fil: Kutok, Jeffery L.. Brigham and Women’s Hospital. Department of Pathology; Estados Unidos | |
| dc.description.fil | Fil: Shipp, Margaret A.. Dana-Farber Cancer Institute. Department of Medical Oncology; Estados Unidos | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Ouyang, Ying; Juszczynski, Przemyslaw; Rodig, Scott J.; Green, Michael R.; O´ Donnell, Evan; et al.; Viral induction and targeted inhibition of galectin-1 in EBV + posttransplant lymphoproliferative disorders; American Society Of Hematology; Blood, The Journal Of The American Society Of Hematology - Print; 117; 16; 6-2011; 4315-4322 | es |
| dc.identifier.issn | 0006-4971 | es |
| dc.identifier.uri | http://hdl.handle.net/11336/10661 | |
| dc.journal.ciudad | Washington | es |
| dc.journal.number | 16 | es |
| dc.journal.pagination | 4315-4322 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Blood, The Journal Of The American Society Of Hematology - Print | es |
| dc.journal.volume | 117 | es |
| dc.language.iso | eng | es |
| dc.publisher | American Society Of Hematology | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/http://www.bloodjournal.org/content/117/16/4315?sso-checked=true | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http:/dx.doi.org/10.1182/blood-2010-11-320481 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | es |
| dc.subject | Epstein Barr-Virus | es |
| dc.subject | Lymphoproliferative Disorders | es |
| dc.subject | Galectin-1 | es |
| dc.subject | Transplantation | es |
| dc.subject.classification | Bioquímica y Biología Molecular | es |
| dc.subject.classification | Medicina Básica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Viral induction and targeted inhibition of galectin-1 in EBV + posttransplant lymphoproliferative disorders | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.14287.pdf
- Tamaño:
- 489.76 KB
- Formato:
- Adobe Portable Document Format